IP Library › Granted Patent US 12,531,138
Granted Patent B2
US 12,531,138 · App. 17/305,366 · Granted Jan 20, 2026

Parameterized template for clinical research study systems

Inventors: Frederik Malfait (Wolfenschiessen, CH); Brent Carlson (Minneapolis, MN); Tim Graser (Spring Valley, MN); Mark Watson (Bryan, TX); Robert Ross (Lumberton, NJ); Maurice Williams (Canton, MI); LeFether Jackson (Thousand Oaks, CA); Tuan Dinh (Hamilton, OH)
Assignee: Nurocor, Inc.
G16H10/20G06F3/0486G06F8/34G06F16/211G06F16/212G06F16/2246G06F16/2379G06F16/9024G06F16/9027G06F16/907G06F16/908G16H10/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,531,138
App. No.
17/305,366
Granted
Jan 20, 2026
Kind
B2
Abstract

Techniques are disclosed for digitizing a framework for clinical development. In one example, A computing device comprising a memory configured to store a regulatory database, and one or more processors may be configured to perform the techniques. The one or more processors may retrieve, from the regulatory database, a template based on a governance process, receive, via a user interface, input from a user, parameterize the template based on the governance process with the user input to create a parameterized template, and store the parameterized template in a database.

Claims (159)

1 . A method comprising:

retrieving, by processing circuitry and from a regulatory database, a template representative of a governance process;

receiving, by the processing circuitry and via a user interface, input from a user;

parameterizing, by the processing circuitry, the template representative of the governance process with the user input to create a parameterized template, wherein at least one parameter in the parameterized template is a string associated with one or more properties specific to a clinical research study;

generating, by the processing circuitry and based on the parameterized template, at least one study objective and at least one study endpoint for the clinical research study;

processing the at least one of the parameters in the parameterized template to present the at least one of the parameters as a human readable phrase that takes into account grammatical rules in support of disclosure submissions mandated by one or more regulatory authorities;

generating, by the processing circuitry and based on the at least one study objective and the at least one study endpoint, a sequence of one or more study events specifying one or more study activities to be executed for the sequence of the one or more study events;

exporting, by the processing circuitry and to one or more of the regulatory database and a microservice, metadata for the clinical research study,

wherein exporting the metadata for the clinical research study comprises:

retrieving, by the processing circuitry and from the database, a graph data structure representative of the clinical research study;

generating, by the processing circuitry and from the graph data structure representative of the clinical research study, a tree data structure representative of the metadata for the clinical research study; and

storing, by the processing circuitry and in the regulatory database, the tree data structure representative of the metadata for the clinical research study; and

storing, by the processing circuitry, the parameterized template in a database.

2 . The method of claim 1 , wherein exporting the metadata for the clinical research study comprises exporting the metadata for the clinical research study according to a predefined file format through configurable transformations.

3 . The method of claim 1 , further comprising defining, by the processing circuitry and based on the parameterized template, a database for storing data specifying the details of the clinical research study.

4 . The method of claim 1 , wherein the regulatory database comprises a metadata repository (MDR) database.

5 . The method of claim 4 , wherein the MDR database comprises one or more of an International Organization for Standardization (ISO) 11179-based MDR database, wherein the ISO 11179-based MDR database is hierarchically arranged with respect to a global organizational group containing shared template definition elements, and one or more sponsor-specific-based organizational subgroups containing sponsor-specific template definition elements, with the hierarchy facilitating reuse of the content contained within the global organizational group without compromising access limitations with respect to the sponsor-specific-based subgroups.

6 . The method of claim 1 , wherein the database is configured to receive a GraphQL query or mutation.

7 . The method of claim 1 , further comprising:

defining a data model comprising the metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, each client business object specifying the one or more study events or associated study elements; and

expressing, by the processing circuitry, the data model to define the template for a clinical research study comprising the sequence of the one or more study events.

8 . The method of claim 7 , wherein parameterizing the template for the clinical research study comprises parameterizing the template to obtain a schedule of study activities to be executed for each study event of the sequence of the one or more study events.

9 . The method of claim 1 , further comprising:

defining a data model comprising metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, and the one or more properties for each of the client business objects that organize the client business objects into one or more property groups; and

expressing, by the processing circuitry, the data model to produce, based on one or more of the properties and property groups, forms for collection of protocol elements in support of generating the template.

10 . The method of claim 1 , further comprising:

defining a data model comprising the metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, and the one or more properties for each of the client business objects that organize the client business objects into one or more property groups; and

expressing, by the processing circuitry, one or more of the one or more properties and the property group for each of the client business objects to define:

one or more study objective templates; and

one or more study endpoint templates.

11 . The method of claim 1 , wherein each study activity of the one or more study activities is selected from a group comprising at least:

a clinical treatment or procedure to be performed on a subject;

a data element to be measured from the subject; or

non-treatment related data of the subject.

12 . The method of claim 1 , wherein each property of the one or more properties specifies a value for a property type for the property, the property type selected from a property group comprising the string and at least:

a dynamically generated list of users;

a date;

a time;

a uniform resource locator (URL);

a Boolean;

a member of an pre-defined list; or

an integer.

13 . The method of claim 1 , wherein at least one of the one or more properties include dynamically generated value sets.

14 . The method of claim 1 , wherein each of the one or more properties are strongly typed.

15 . The method of claim 1 , wherein each of the one or more properties specifies a dependent relationship to another property of the one or more properties.

16 . The method of claim 1 , wherein the one or more properties includes a compound property having two or more values.

17 . The method of claim 1 , further comprising:

presenting, by the processing circuitry, via the user interface, and to the user, the clinical research study.

18 . The method of claim 17 , wherein the clinical research study further comprises one or more study elements associated with the one or more study events.

19 . The method of claim 17 , wherein parameterizing the template representative of the governance process with the user input to create the parameterized template comprises:

displaying, by the processing circuitry, via the user interface, and to the user, one or more input types and one or more values for each of the one or more input types, and

receiving, via the user interface and from the user, a selection of a value of the one or more values for each of the one or more input types; and

parameterizing the template representative of the governance process with the selection of the value of the one or more values for each of the one or more input types to create the parameterized template.

20 . The method of claim 19 , wherein the one or more study design elements are immutable and assist in access control when binding users to the clinical research study.

21 . The method of claim 17 , wherein receiving the input from the user comprises receiving a user input specifying one or more secondary or exploratory study objectives or one or more secondary or exploratory study endpoints.

22 . The method of claim 17 , further comprising:

determining, by the processing circuitry, a cost estimate for the one or more study activities to be executed for each study event of the one or more study events;

determining, by the processing circuitry and based on the cost estimate for the one or more study activities to be executed for each study event of the one or more study events, a total cost estimate for the at least one study endpoint; and

displaying, by the processing circuitry and via the user interface, the cost estimate for the one or more study activities to be executed for each study event of the one or more study events and the total cost estimate for the at least one study endpoint.

23 . The method of claim 17 , further comprising:

determining, by the processing circuitry and based on the sequence of the one or more study events, a timeline for the clinical research study; and

displaying, by the processing circuitry and via the user interface, the timeline for the clinical research study.

24 . The method of claim 23 , wherein the timeline further comprises a schedule for each of the one or more study activities to be executed for each study event of the one or more study events.

25 . The method of claim 17 , wherein presenting, via the user interface, the clinical research study comprises presenting, via user interface embedded within a dashboard web application, the clinical research study.

26 . The method of claim 17 , further comprising:

generating, by the processing circuitry and based on the parameterized template, one or more reporting criteria for the clinical research study; and

displaying, by the processing circuitry and via the user interface, one or more reporting criteria for the clinical research study.

27 . The method of claim 1 ,

wherein receiving the input from the user includes receiving data indicative of an Effective Date parameter, and

wherein parameterizing the template comprises associating the Effective Date parameter to a correct version of the template representative of the governance process associated with the Effective Date parameter.

28 . The method of claim 9 , wherein each property group of the one or more property groups specifies at least one of:

an ordinality of the property group in a property group hierarchy; or

a microservice associated with the property group.

29 . A computing device comprising:

a memory configured to store a regulatory database; and

one or more processors configured to:

retrieve, from the regulatory database, a template representative of a governance process;

receive, via a user interface, input from a user;

parameterize the template representative of the governance process with the user input to create a parameterized template, wherein at least one parameter in the parameterized template is a string associated with one or more properties specific to a clinical research study;

generate, based on the parameterized template, at least one study objective and at least one study endpoint for the clinical research study;

process at least one of the parameters in the parameterized template to present the at least one of the parameters as a human readable phrase that takes into account grammatical rules in support of disclosure submissions mandated by one or more regulatory authorities;

generate, based on the at least one study objective and the at least one study endpoint, a sequence of one or more study events specifying one or more study activities to be executed for the sequence of the one or more study events;

exporting, to one or more of the regulatory database and a microservice, metadata for the clinical research study,

wherein to export the metadata for the clinical research study, the one or more processors are configured to:

retrieve, from the database, a graph data structure representative of the clinical research study;

generate, from the graph data structure representative of the clinical research study, a tree data structure representative of the metadata for the clinical research study; and

store, by the processing circuitry and in the regulatory database, the tree data structure representative of the metadata for the clinical research study; and

store the parameterized template in a database.

30 . The computing device of claim 29 , wherein the one or more processors are configured, when exporting the metadata for the clinical research study, to export the metadata for the clinical research study according to a predefined file format through configurable transformations.

31 . The computing device of claim 29 , the one or more processors are further configured to define, based on the parameterized template, a database for storing data specifying the details of the clinical research study.

32 . The computing device of claim 29 , wherein the regulatory database comprises a metadata repository (MDR) database.

33 . The computing device of claim 32 , wherein the MDR database comprises one or more of an International Organization for Standardization (ISO) 11179-based MDR database, wherein the ISO 11179-based MDR database is hierarchically arranged with respect to a global organizational group containing shared template definition elements, and one or more sponsor-specific-based organizational subgroups containing sponsor-specific template definition elements, with the hierarchy facilitating reuse of the content contained within the global organizational group without compromising access limitations with respect to the sponsor-specific-based subgroups.

34 . The computing device of claim 29 , wherein the database is configured to receive a GraphQL query or mutation.

35 . The computing device of claim 29 , the one or more processors are further configured to:

define a data model comprising the metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, each client business object specifying one or more study events or associated study elements and express the data model to define the template for a clinical research study comprising the sequence of the one or more study events.

36 . The computing device of claim 35 , wherein the one or more processors are configured, when parameterizing the template for the clinical research study, to parameterize the template to obtain a schedule of study activities to be executed for each study event of the sequence of the one or more study events.

37 . The computing device of claim 29 , the one or more processors are further configured to:

define a data model comprising metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, and one or more properties for each of the client business objects that organize the client business objects into one or more property groups; and

express the data model to produce, based on one or more of the properties and property groups, forms for collection of protocol elements in support of generating the template.

38 . The computing device of claim 29 , the one or more processors are further configured to:

define a data model comprising the metadata that specifies a data standard representative of requirements for regulatory-compliant exchange of data between entities, wherein the data model includes one or more client business objects, and one or more properties for each of the client business objects that organize the client business objects into one or more property groups; and

express one or more of the one or more properties and the property group for each of the client business objects to define:

one or more study objective templates; and

one or more study endpoint templates.

39 . The computing device of claim 29 , wherein each study activity of the one or more study activities is selected from a group comprising at least:

a clinical treatment or procedure to be performed on a subject;

a data element to be measured from the subject; or

non-treatment related data of the subject.

40 . The computing device of claim 29 , wherein each property of the one or more properties specifies a value for a property type for the property, the property type selected from a group comprising the string and at least:

a dynamically generated list of users;

a date;

a time;

a uniform resource locator (URL);

a Boolean;

a member of an pre-defined list; or an integer.

41 . The computing device of claim 29 , wherein at least one of the one or more properties include dynamically generated value sets.

42 . The computing device of claim 29 , wherein each of the one or more properties are strongly typed.

43 . The computing device of claim 29 , wherein each of the one or more properties specifies a dependent relationship to another property of the one or more properties.

44 . The computing device of claim 29 , wherein the one or more properties includes a compound property having two or more values.

45 . The computing device of claim 29 , the one or more processors are further configured to:

present, via the user interface, and to the user, the clinical research study.

46 . The computing device of claim 45 , wherein the clinical research study further comprises one or more study elements associated with the one or more study events.

47 . The computing device of claim 45 , wherein the one or more processors are configured, when parameterizing the template representative of the governance process with the user input to create the parameterized template, to:

display, via the user interface, and to the user, one or more input types and one or more values for each of the one or more input types, and

receive, via the user interface and from the user, a selection of a value of the one or more values for each of the one or more input types; and

parameterize the template representative of the governance process with the selection of the value of the one or more values for each of the one or more input types to create the parameterized template.

48 . The computing device of claim 47 , wherein the one or more study design elements are immutable and assist in access control when binding users to the clinical research study.

49 . The computing device of claim 45 , wherein the one or more processors are configured, when receiving the input from the user, to receive a user input specifying one or more secondary or exploratory study objectives or one or more secondary or exploratory study endpoints.

50 . The computing device of claim 45 , the one or more processors are further configured to:

determine a cost estimate for the one or more study activities to be executed for each study event of the one or more study events;

determine, based on the cost estimate for the one or more study activities to be executed for each study event of the one or more study events, a total cost estimate for the at least one study endpoint; and

display, via the user interface, the cost estimate for the one or more study activities to be executed for each study event of the one or more study events and the total cost estimate for the at least one study endpoint.

51 . The computing device of claim 45 , the one or more processors are further configured to:

determine, based on the sequence of the one or more study events, a timeline for the clinical research study; and

display, via the user interface, the timeline for the clinical research study.

52 . The computing device of claim 51 , wherein the timeline further comprises a schedule for each of the one or more study activities to be executed for each study event of the one or more study events.

53 . The computing device of claim 45 , wherein the one or more processors are configured, when presenting, via the user interface, the clinical research study, to present, via user interface embedded within a dashboard web application, the clinical research study.

54 . The computing device of claim 45 , wherein the one or more processors are further configured to:

generate, based on the parameterized template, one or more reporting criteria for the clinical research study; and

display, via the user interface, one or more reporting criteria for the clinical research study.

55 . The computing device of claim 29 ,

wherein the one or more processors are configured, when receiving the input from the user, to receive data indicative of an Effective Date parameter, and

wherein the one or more processors are configured, when parameterizing the template, to associate the Effective Date parameter to a correct version of the template representative of the governance process associated with the Effective Date parameter.

56 . The computing device of claim 29 , wherein each property group of the one or more property groups specifies at least one of:

an ordinality of the property group in a property group hierarchy; or

a microservice associated with the property group.

57 . A non-transitory computer-readable storage medium having instructions stored thereon that, when executed, cause one or more processors to:

retrieve, from a regulatory database, a template representative of a governance process;

receive, via a user interface, input from a user;

parameterize the template representative of the governance process with the user input to create a parameterized template, wherein at least one parameter in the parameterized template is a string associated with one or more properties specific to a clinical research study;

generate, based on the parameterized template, at least one study objective and at least one study endpoint for the clinical research study;

processing at least one of the parameters in the parameterized template to present the at least one of the parameters as a human readable phrase that takes into account grammatical rules in support of disclosure submissions mandated by one or more regulatory authorities;

generate, based on the at least one study objective and the at least one study endpoint, a sequence of one or more study events specifying one or more study activities to be executed for the sequence of the one or more study events;

exporting, to one or more of the regulatory database and a microservice, metadata for the clinical research study,

wherein to export the metadata for the clinical research study, the one or more processors are configured to:

retrieve, from the database, a graph data structure representative of the clinical research study;

generate, from the graph data structure representative of the clinical research study, a tree data structure representative of the metadata for the clinical research study; and

store, by the processing circuitry and in the regulatory database, the tree data structure representative of the metadata for the clinical research study; and

store the parameterized template in a database.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2021
From: MALFAIT, FREDERIK; CARLSON, BRENT; GRASER, TIM; WATSON, MARK; ROSS, ROBERT; WILLIAMS, MAURICE; JACKSON, LEFETHER; DINH, TUAN
To: NUROCOR, INC.
Reel/Frame 058361/0922 →
Continuity (3)
Provisional Application 63198657 · Nov 2, 2020
Provisional Application 63048375 · Jul 6, 2020
Related Publication 20220005554A1 · Jan 6, 2022
References Cited (191)
US D344102S · Polak et al. · 1994 [cited by applicant]
US D502184S · Glezer et al. · 2005 [cited by applicant]
US 7030890B1 · Jouet et al. · 2006 [cited by applicant]
US D594911S · Hall et al. · 2009 [cited by applicant]
US 7818689B2 · Wada · 2010 [cited by applicant]
US 8041735B1 · Lacapra et al. · 2011 [cited by applicant]
US 8286072B2 · Chamberlain et al. · 2012 [cited by applicant]
US D673577S · Cojuangco et al. · 2013 [cited by applicant]
US 8527920B1 · Choudhury et al. · 2013 [cited by applicant]
US D698361S · Stiffler · 2014 [cited by applicant]
US D714334S · Cojuangco et al. · 2014 [cited by applicant]
US D715834S · Siddons · 2014 [cited by applicant]
US D723048S · Helliker et al. · 2015 [cited by applicant]
US D732058S · Landis et al. · 2015 [cited by applicant]
US D740840S · Zhang et al. · 2015 [cited by applicant]
US D753140S · Kouvas et al. · 2016 [cited by applicant]
US D753174S · Cojuangco et al. · 2016 [cited by applicant]
US D759072S · Siddons · 2016 [cited by applicant]
US D769315S · Scotti · 2016 [cited by applicant]
US D771107S · Spector · 2016 [cited by applicant]
US D772276S · Yampolskiy et al. · 2016 [cited by applicant]
US D776133S · Hill et al. · 2017 [cited by applicant]
US D788790S · Omata · 2017 [cited by applicant]
US D792448S · Take et al. · 2017 [cited by applicant]
US D799499S · Selden et al. · 2017 [cited by applicant]
US D803248S · Sunshine et al. · 2017 [cited by applicant]
US D819687S · Yampolskiy et al. · 2018 [cited by applicant]
US D841030S · Bradley-Pollack et al. · 2019 [cited by applicant]
US D841031S · Orlando et al. · 2019 [cited by applicant]
US D841675S · Hoffman et al. · 2019 [cited by applicant]
US D854558S · Melillo et al. · 2019 [cited by applicant]
US D855634S · Kim · 2019 [cited by applicant]
US D870762S · Mendoza Corominas et al. · 2019 [cited by applicant]
US D872121S · Einspahr et al. · 2020 [cited by applicant]
US D873846S · Melillo et al. · 2020 [cited by applicant]
US D876445S · Ting et al. · 2020 [cited by applicant]
US D877747S · Belliveau · 2020 [cited by applicant]
US D880517S · Imamura et al. · 2020 [cited by applicant]
US D881927S · Tsukahara et al. · 2020 [cited by applicant]
US D882598S · Belliveau · 2020 [cited by applicant]
US 10613711B1 · Makovsky et al. · 2020 [cited by applicant]
US D895642S · Hoofnagle et al. · 2020 [cited by applicant]
US D898054S · Everhart et al. · 2020 [cited by applicant]
US D900836S · Burnell et al. · 2020 [cited by applicant]
US D900840S · Dudey · 2020 [cited by applicant]
US D914046S · Tsukahara et al. · 2021 [cited by applicant]
US D916869S · Evangeliou et al. · 2021 [cited by applicant]
US D922422S · Molander et al. · 2021 [cited by applicant]
US D924906S · Nie et al. · 2021 [cited by applicant]
US D924909S · Nasu et al. · 2021 [cited by applicant]
US D928194S · Baker et al. · 2021 [cited by applicant]
US D929431S · Streifert et al. · 2021 [cited by applicant]
US D931314S · Xie et al. · 2021 [cited by applicant]
US 11132552B1 · Naslavsky et al. · 2021 [cited by applicant]
US D937862S · Anderson et al. · 2021 [cited by applicant]
US D940172S · Xie et al. · 2022 [cited by applicant]
US D946615S · Einspahr et al. · 2022 [cited by applicant]
US D950580S · Ahmed · 2022 [cited by applicant]
US D959446S · Doddi et al. · 2022 [cited by applicant]
US D959448S · Lee · 2022 [cited by applicant]
US D960173S · Steppan et al. · 2022 [cited by applicant]
US D962982S · Wolff · 2022 [cited by applicant]
US D963677S · Bahatyrevich · 2022 [cited by applicant]
US D964386S · Bill · 2022 [cited by applicant]
US D978887S · Caro et al. · 2023 [cited by applicant]
US D980863S · Balsamo et al. · 2023 [cited by applicant]
US D982596S · Sapre et al. · 2023 [cited by applicant]
US D985602S · Walecka et al. · 2023 [cited by applicant]
US D986271S · Shor · 2023 [cited by applicant]
US D987670S · Soerhaug et al. · 2023 [cited by applicant]
US D989122S · Griego et al. · 2023 [cited by applicant]
US D997194S · Simon · 2023 [cited by applicant]
US D998628S · Dinga et al. · 2023 [cited by applicant]
US D998629S · Dinga et al. · 2023 [cited by applicant]
US D1011375S · Miyaki et al. · 2024 [cited by applicant]
US D1031742S · Feldmann et al. · 2024 [cited by applicant]
US D1040175S · Potash · 2024 [cited by applicant]
US D1045896S · Zhou et al. · 2024 [cited by applicant]
US D1045919S · Zhou et al. · 2024 [cited by applicant]
US D1052603S · Ganapathy · 2024 [cited by applicant]
US D1055947S · Harmon et al. · 2024 [cited by applicant]
US D1060404S · Arora · 2025 [cited by applicant]
US D1061592S · Khokhar et al. · 2025 [cited by applicant]
US D1076936S · Chen et al. · 2025 [cited by applicant]
US D1076964S · Ganapathy · 2025 [cited by applicant]
US D1081702S · Malfait et al. · 2025 [cited by applicant]
US 20040249664A1 · Broverman et al. · 2004 [cited by applicant]
US 20050055241A1 · Horstmann · 2005 [cited by examiner]
US 20050138635A1 · Auerbach et al. · 2005 [cited by applicant]
US 20050256380A1 · Nourie et al. · 2005 [cited by applicant]
US 20070174305A1 · Arocena · 2007 [cited by applicant]
US 20080104141A1 · McMahon · 2008 [cited by applicant]
US 20080120573A1 · Gilbert et al. · 2008 [cited by applicant]
US 20080120574A1 · Heredia et al. · 2008 [cited by applicant]
US 20090313048A1 · Kahn · 2009 [cited by examiner]
US 20100118871A1 · Liu et al. · 2010 [cited by applicant]
US 20110153358A1 · Campo · 2011 [cited by examiner]
US 20120035954A1 · Yeskel · 2012 [cited by applicant]
US 20120101838A1 · Lingard et al. · 2012 [cited by applicant]
US 20130232104A1 · Goyal et al. · 2013 [cited by applicant]
US 20140039921A1 · Broverman et al. · 2014 [cited by applicant]
US 20140222444A1 · Cerello et al. · 2014 [cited by applicant]
US 20140280363A1 · Heng et al. · 2014 [cited by applicant]
US 20150142330A1 · Yeang et al. · 2015 [cited by applicant]
US 20150213547A1 · Gomez-Rosado et al. · 2015 [cited by applicant]
US 20150222495A1 · Mehta et al. · 2015 [cited by applicant]
US 20170075557A1 · Noble et al. · 2017 [cited by applicant]
US 20170116373A1 · Ginsburg et al. · 2017 [cited by applicant]
US 20170147794A1 · Harder et al. · 2017 [cited by applicant]
US 20170286456A1 · Wenzel et al. · 2017 [cited by applicant]
US 20170323320A1 · Mendoza Corominas et al. · 2017 [cited by applicant]
US 20170357778A1 · Archer et al. · 2017 [cited by applicant]
US 20180039399A1 · Kaltegaertner et al. · 2018 [cited by applicant]
US 20180261305A1 · Lindblad et al. · 2018 [cited by applicant]
US 20200177710A1 · Wyatt · 2020 [cited by examiner]
US 20200335188A1 · Ozeran · 2020 [cited by applicant]
US 20200394612A1 · Khokhar et al. · 2020 [cited by applicant]
US 20210241859A1 · Bhattacharya et al. · 2021 [cited by applicant]
US 20220004540A1 · Watson et al. · 2022 [cited by applicant]
US 20220005555A1 · Malfait et al. · 2022 [cited by applicant]
US 20220005558A1 · Malfait et al. · 2022 [cited by applicant]
US 20220248988A1 · Kumar et al. · 2022 [cited by applicant]
US 20230274809A1 · Dimitrova · 2023 [cited by examiner]
US 20230360779A1 · Gnanasambandam · 2023 [cited by examiner]
WO 2014033747A2 · 2014 [cited by applicant]
Jian et al. (“Using Semantic Web Technologies for the generation of domain-specific templates to support clinical study metadata standards”; Journal of Biomedical Semantics (2016)) (Year: 2016). [cited by examiner]
Response to Communication Pursuant to Rules 161(1) and 162 EPC dated Feb. 14, 2013, from counterpart European Application No. 21749512.6, filed Aug. 11, 2023, 34 pp. [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC dated Feb. 14, 2023, from counterpart European Application No. 21749513.4, filed Aug. 9, 2023, 25 pp. [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC dated Feb. 16, 2023, from counterpart European Application No. 21749511.8, filed Aug. 16, 2023, 30 pp. [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC dated Feb. 16, 2023, from counterpart European Application No. 21749514.2, filed Aug. 25, 2023, 34 pp. [cited by applicant]
Response to Office Action dated Jun. 5, 2023 from U.S. Appl. No. 29/652,731, filed Sep. 1, 2023, 7 pp. [cited by applicant]
Kemegne et al., “Comparing checkerboard, isobologram and CCD methods for drug combination” A case study of ciprofloxacin and plant extracts on [cited by applicant]
Notice of Allowance from U.S. Appl. No. 29/652,731 dated Nov. 13, 2023, 11 pp. [cited by applicant]
International Preliminary Report on Patentability from International Application No. PCT/US2021/070827 dated Jan. 19, 2023, 12 pp. [cited by applicant]
“Biotech Out-Licensed Optimized Compound Value—Product Oriented Licensing Strategy,” Intilaris LifeSciences, accessed on Sep. 9, 2020, 6 pp. [cited by applicant]
“Clinical trials and their patients: The rising costs and how to stem the loss,” Pharmafile, accessed from http:/www.pharmafile.com/print/511225, Mar. 11, 2016, 6 pp. [cited by applicant]
“Cost of Developing a New Drug,” Tufts Center for the Study of Drug Development (CSDD), Tufts University, School of Medicine, Nov. 18, 2014, 30 pp. [cited by applicant]
“Digital Data Flow Solution Framework and Conceptual Design, Version 1.0,” TransCelebrate DDF Project Team, TransCelebrate Biopharma, Inc., Nov. 1, 2019, 46 pp. [cited by applicant]
“Drug Approval Process—Infographic,” U.S. Food and Drug Administration (FDA), accessed from http://www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/UCM284393.pdf, accessed on Jan. 20, 2015, 2 pp. [cited by applicant]
“Executive Summary—Digital Data Flow Solution Framework and Conceptual Design, Version 1.0,” TransCelebrate Biopharma, Inc., Nov. 7, 2019, 4 pp. [cited by applicant]
“Facts about Clinical Trials,” Arena International, accessed from https://web.archive.org/web/20180914235739/http://www.arena-international.com/clinicaltrials/facts-about-clinical-trials/1063.article, dated Sep. 14, 201… [cited by applicant]
“How to avoid costly clinical research delays,” MESM Blog, accessed from https://www.mesm.com/blog/tips-to-help-you-avoid-costly-clinical-research-delays/, dated Jan. 16, 2020, accessed on Mar. 4, 2021, 4 pp. [cited by applicant]
“ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guidelin on statistical principles for clinical trials,” European Medicines Agency, Committee for Medicinal Products for Human Use, E… [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 1: Framework,” International Standards, ISO/IEC 11179-1, Second Edition, Sep. 15, 2004, 32 pp. [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 2: Classification,” International Standards, ISO/IEC 11179-2, Second Edition, Nov. 15, 2005, 16 pp. [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 3: Registry metamodel and basic attributes,” International Standards, ISO/IEC 11179-3, Third Edition, Feb. 15, 2013, 244 pp. [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 4: Formulation of data definitions,” International Standards, ISO/IEC 11179-4, Second Edition, Jul. 15, 2004, 16 pp. [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 5: Naming principles,” International Standards, ISO/IEC 11179-5, Third Edition, Apr. 1, 2015, 32 pp. [cited by applicant]
“Information technology—Metadata registries (MDR)—Part 6: Registration,” International Standards, ISO/IEC 11179-6, Third Edition, Aug. 1, 2015, 72 pp. [cited by applicant]
“Nurocor Clinical Platform—Technical Perspective,” Nurocor, Inc., accessed on Apr. 29, 2020, 11 pp. [cited by applicant]
“Optimize Clinical Development,” Nurocor and Intilaris brochure, accessed on Sep. 9, 2020, 2 pp. [cited by applicant]
“Reusable Asset Specification, Version 2.2,” Object Management Group (OMG), accessed from https://www.omg.org/spec/RAS/2.2/PDF, Nov. 2005, 121 pp. [cited by applicant]
“Streamline Your Clinical Operations Through Smarter Standardization,” Nurocor, PowerPoint presented at 2019 Clinical Data Interchange Standards Consortium (CDISC), US Interchange, San Diego, California, Oct. 18, 2019, … [cited by applicant]
“The Case for CDISC Standards,” CDISC, Business Case for CDISC Standards, Stage V, Sep. 30, 2014, 45 pp. [cited by applicant]
“Nurocor products allow customers to automate clinical development processes from protocol to submission,” NUROCOR Brochure, accessed from www.nurocor.com, accessed on Sep. 10, 2019, 4 pp. [cited by applicant]
“Study Data Tabulation Model Implementation Guide: Human Clinical Trials,” Prepared by the CDISC Submission Standards Team, cdisc, Version 3.3 (Final), Clinical Data Interchange Standards Consortium, Inc., Nov. 20, 2018… [cited by applicant]
Burrows, “Report: The 8 biggest challenges facing clinical trail professionals,” Informa Connect, Clinical & Medical Affairs, accessed from https://informaconnect.com/report-biggest-challenges-clinical-trials-pt-1/, Nov… [cited by applicant]
Ganic et al., “PhUSE EU Connect 2018—Structure and Standardized Study Definition drives early study setup for added business benefits,” Bayer, Intilaris, Nov. 2018, 20 pp. [cited by applicant]
Getz et al., “Measuring the Incidence, Causes, and Repercussions of Protocol Amendments,” Therapeutic Innovation and Regulatory Science, Drug Information Journal, vol. 45, Issue 3, May 2011, pp. 265-275. [cited by applicant]
Grayling et al., “A web application for the design of multi-arm clinical trials,” Arvix.org, Cornell University Library, Jun. 21, 2019. [cited by applicant]
Hargreaves, “Clinical trails and their patients: The rising costs and how to stem the loss,” Pharmafile, accessed from http://www.pharmafile.com/news/511225/clinical-trials-and-their-patients-rising-costs-and-how-stem-l… [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/US2021/070827, dated Jan. 20, 2022, 17 pp. [cited by applicant]
Kountouris et al., “Efficient scheduling of conditional behaviors for high-level synthesis,” ACM Transactions on Design Automation of Electronic Systems, vol. 7, No. 3, Jul. 1, 2002, pp. 380-412. [cited by applicant]
Lin et al., “A Standard-Driven Approach for Electric Submission to Pharmaceutical Regulatory Authorities”, Journal of Biomedical Informatics, vol. 79, Jan. 31, 2018, pp. 60-70. [cited by applicant]
Nelson et al., “3D Standardized in Clinical Development to achieve End-to-End Automation,” Intilaris, Nurocor, 2019 Clinical Data Interchange Standards Consortium (CDISC), Oct. 14-18, 2019, 5 pp. [cited by applicant]
Nelson et al., “CDISC 2019 US Interchange,” [Presentation], CDISC, San Diego, CA, Oct. 14-18, 2019, 19 pp. [cited by applicant]
Nelson et al., PowerPoint presented at 2019 Clinical Data Interchange Standards Consortium (Cdisc) US Interchange, San Diego, California, Oct. 14-18, 2018, 19 pp. [cited by applicant]
Seguine, “Overcoming the Industry's Data Crisis,” Clinical Link, EPC, Aug. 2019, pp. 38-41. [cited by applicant]
Sjobergh et al., “Visualizing Clinical Trial Data Using Pluggable Components,” Information Visualisation, 2012 16th International Conference, Jul. 11, 2012, pp. 291-296. [cited by applicant]
U.S. Appl. No. 29/652,731, filed Nov. 2, 2021, naming inventors Malfait et al. [cited by applicant]
Woodcock et al., “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both, ” Massachusetts Medical Society, The New England Journal of Medicine, Jul. 6, 2017, 9 pp. [cited by applicant]
Office Action from U.S. Appl. No. 29/652,731 dated Jun. 5, 2023, 15 pp. [cited by applicant]
Response to Office Action dated Mar. 8, 2024 from U.S. Appl. No. 17/305,368, filed Jul. 8, 2024, 18 pp. [cited by applicant]
Office Action from U.S. Appl. No. 17/305,368 dated Mar. 8, 2024, 13 pp. [cited by applicant]
Ex Parte Quayle Action from U.S. Appl. No. 30/004,959 dated Jul. 30, 2025, 8 pp. [cited by applicant]
Ex Parte Quayle Action from U.S. Appl. No. 30/004,961 dated Jul. 30, 2025, 9 pp. [cited by applicant]
Office Action from U.S. Appl. No. 17/305,368 dated Jul. 29, 2025, 10 pp. [cited by applicant]
Dandapani et al., “Leveraging Mobile-Based Sensors for Clinical Research”, Frontiers in Digital Health, vol. 4, Jun. 13, 2022, 12 pp. [cited by applicant]
Kriebel, Andy, How to Create a Dot Strip Plot, Jun. 8, 2021, YouTube.com, retrieved Feb. 28, 2025, https://www.youtube.com/watch?v=fKSL-IMqILA. [cited by applicant]
Notice of Allowance from U.S. Appl. No. 29/652,731 dated Mar. 14, 2025, 9 pp. [cited by applicant]
Response to Office Action dated Jan. 6, 2025 from U.S. Appl. No. 17/305,368 filed Apr. 7, 2025, 16 pp. [cited by applicant]
Final Office Action from U.S. Appl. No. 17/305,368 dated Apr. 22, 2025, 16 pp. [cited by applicant]
Corrected Notice of Allowance from U.S. Appl. No. 39/652,731 dated May 20,2025, 3 pp. [cited by applicant]
Response to Final Office Action dated Apr. 22, 2025 from U.S. Appl. No. 17/305,368 filed Jun. 19, 2025, 15 pp. [cited by applicant]
Advisory Action from U.S. Appl. No. 17/305,368 dated Jun. 26, 2025, 3 pp. [cited by applicant]
Murray, “Lazy object copy as a platform for polulation-based probabilistic programming”, Jan. 9, 2020, 16 pp. [cited by applicant]
Office Action from U.S. Appl. No. 17/305,368 dated Sep. 18, 2024, 15 pp. [cited by applicant]
Office Action from U.S. Appl. No. 17/305,368 dated Jan. 6, 2025, 15 pp. [cited by applicant]
Response to Final Office Action dated Sep. 18, 2024 from U.S. Appl. No. 17/305,368, filed Dec. 17, 2024, 17 pp. [cited by applicant]
Response to Ex Parte Quayle Action dated Jul. 30, 2025 from U.S. Appl. No. 30/004,959, filed Sep. 17, 2025, 5 pp. [cited by applicant]
Response to Ex Parte Quayle Action dated Jul. 30, 2025 from U.S. Appl. No. 30/004,961, filed Sep. 17, 2025, 5 pp. [cited by applicant]